The Board of Directors of STAR Pharmaceutical Limited. provided consolidated earnings guidance for the fourth quarter and year ended December 31, 2012. The Group is expects to report a loss for the fourth quarter of 2012 and the financial year ended December 31, 2012.

The Group's financial results were adversely affected by a substantial write-off of an intangible asset of Category I Chinese Medicine Drug, Yanning Capsules, and allowance for impairment of deposit due to termination contract of R&D patent right acquisition.